Literature DB >> 18020580

Thymalfasin: clinical pharmacology and antiviral applications.

A Gramenzi1, C Cursaro, P Andreone, M Bernardi.   

Abstract

Thymalfasin (thymosin-alpha1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with interferon-alpha for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.

Entities:  

Year:  1998        PMID: 18020580     DOI: 10.2165/00063030-199809060-00005

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  6 in total

1.  Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment.

Authors:  Yang Hyun Baek; Sung Wook Lee; Hyun Seung Yoo; Hyun Ah Yoon; Ja Won Kim; Young Hoon Kim; Ha Youn Kim; Sang Young Han
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

Review 2.  Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Viruses       Date:  2020-09-26       Impact factor: 5.048

4.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

5.  Thymosin as a possible therapeutic drug for COVID-19: A case report.

Authors:  Qiong Na Zheng; Mei Yan Xu; Fang Min Gan; Sha Sha Ye; Hui Zhao
Journal:  World J Clin Cases       Date:  2021-06-06       Impact factor: 1.337

Review 6.  Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis.

Authors:  Yuan-Yuan Zhang; En-Qiang Chen; Jin Yang; Yu-Rong Duan; Hong Tang
Journal:  Virol J       Date:  2009-05-25       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.